Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease

Recruiting now

Conditions studied: Parkinson's Disease

In brief

Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.

Key facts

Study ID

NCT06937034

Run by

AbbVie

People needed

2000

Starts

2025-04-14

Expected to finish

2025-12-01

Last updated by the study team

2025-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.

Where it is running

• Medisch Spectrum Twente /ID# 276695 — Enschede, Overijssel, Netherlands (enrolling)
• Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 — Timișoara, Timiș County, Romania (enrolling)
• Karolinska University Hospital Solna /ID# 277116 — Solna, Stockholm County, Sweden (enrolling)
• Medizinische Universitaet Graz /ID# 278569 — Graz, Styria, Austria

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.